<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26498435</article-id>
      <article-id pub-id-type="pmc">4619329</article-id>
      <article-id pub-id-type="publisher-id">432</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-015-0432-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Renal-type clear cell carcinoma of the prostate: a diagnostic challenge</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Patne</surname>
            <given-names>Shashikant C. U.</given-names>
          </name>
          <address>
            <phone>+91-542-6703357</phone>
            <email>scupatne@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johri</surname>
            <given-names>Nidhi</given-names>
          </name>
          <address>
            <email>johri.nidhi2712@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Katiyar</surname>
            <given-names>Richa</given-names>
          </name>
          <address>
            <email>drrichakati@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trivedi</surname>
            <given-names>Sameer</given-names>
          </name>
          <address>
            <email>drsameertrivedi@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dwivedi</surname>
            <given-names>Uday Shankar</given-names>
          </name>
          <address>
            <email>hodurology@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005 UP India </aff>
        <aff id="Aff2"><label/>Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221 005 UP India </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>193</elocation-id>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>10</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Patne et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>A 72-year-old male presented with urinary symptoms. His serum prostate specific antigen level was 65.2&#xA0;ng/ml. His radical prostatectomy specimen showed clear cell lesion reminiscent of the clear cell renal cell carcinoma along with acinar type of prostatic adenocarcinoma, Gleason score 4&#x2009;+&#x2009;4. The lesional clear cells were positive for pancytokeratin, epithelial membrane antigen, CD10, vimentin, and AMACR while negative for 34&#x3B2;E12, CK7, prostate specific antigen, and PAX8. The final diagnosis was renal-type clear cell carcinoma of the prostate. A follow-up of 20&#xA0;months did not show metastasis. We herein report fifth case of renal-type clear cell carcinoma of the prostate.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Renal cell carcinoma</kwd>
        <kwd>Male</kwd>
        <kwd>Prostate-specific antigen</kwd>
        <kwd>Prostatectomy</kwd>
        <kwd>Prostatic neoplasms</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Occurrence of clear cell lesions in the prostate is rare and diagnostically challenging with variety of possible diagnoses. These include clear cell variants of commonly seen prostatic adenocarcinoma and transitional cell carcinoma together with uncommonly encountered clear cell carcinoma of mullerian type, metastatic renal cell carcinoma, and a recently described entity, renal-type clear cell carcinoma (RTCCC) of the prostate [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. RTCCC occurring in the prostate is an extremely unusual malignant tumor with only four previously published case reports [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>]. We herein report fifth case of RTCCC of the prostate and review pertinent literature.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 72-year-old man came to Urology OPD for evaluation of urinary frequency, urgency, and difficulty. His rectal examination revealed grade II enlargement of the prostate that was firm on palpation. His urine examination was positive for occult blood and 50&#x2013;70 pus cells/high power fields. His serum prostate specific antigen (PSA) level was 65.2&#xA0;ng/ml (normal &lt;4&#xA0;ng/ml). Cystoscopy of the patient showed edematous prostatic urethra and occluding lateral and median lobes of the prostate. Ultrasound and magnetic resonance imaging (MRI) examination showed enlarged prostate without any obvious abnormally enhancing mass lesion in the prostatic parenchyma, and unremarkable appearance of bilateral kidneys, urinary bladder, urethra and rest of the pelvic organs. Needle core biopsy of the prostate revealed adenocarcinoma. His 99mTc-methylene diphosphonate (MDP) scans were negative for bony metastasis. The patient underwent radical prostatectomy and bilateral pelvic lymph node dissection. Grossly, the prostate was 5.5&#x2009;&#xD7;&#x2009;4.5&#x2009;&#xD7;&#x2009;3.5&#xA0;cm in size, cut surface revealed solid grey white areas occupying whole of the prostate except for a thin rim of normal prostate at periphery. Entire prostate gland was embedded in paraffin blocks. Microscopy showed infiltration of the prostatic parenchyma by confluent nests of epithelial cells reminiscent of clear cell carcinoma of renal origin. The epithelial cells showed enlarged centrally located nuclei, conspicuous nucleoli, and abundant clear cytoplasm (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). The tumor nests were surrounded by fibrovascular septa that contained lymphocytic infiltrates. Cytoplasm of few of the clear cells contained periodic acid Schiff positive droplets. Additionally, multiple foci of usual prostatic adenocarcinoma of acinar type (Gleason&#x2019;s score 4&#x2009;+&#x2009;4) were present. With standard immunohistochemical procedure on paraffin sections, the clear cells were immunoreactive for cytokeratin cocktail (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>), CD10 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>), and epithelial membrane antigen. Immunoreactivity for PSA was seen in the areas of usual prostatic acinar adenocarcinoma, but negative in the clear cell areas (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>). The clear cells did not show immunoreactivity against high molecular weight cytokeratin (HMWCK) 34&#x3B2;E12, and CK7. Tumor infiltration was present in all blocks of the prostate from apex to base. Bilateral vas deferens and seminal vesicles were free of tumor. Initially, we thought of metastasis from clear cell carcinoma of renal origin. Subsequently, pre-operative MRI scans were reviewed, which did not reveal any lesion in kidney, urinary bladder, or urethra. Additional immunohistochemistry was performed, which revealed immunoreactivity of the clear cells for vimentin and alpha-methylacyl-CoA racemase (AMACR), and negative immunostaining for PAX8. After extensive literature search and review of histopathology slides, the lesion was diagnosed as RTCCC of the prostate. The patient did not give any history of receiving hormone therapy prior to surgery. There was no history or radiological evidence suggestive of von Hippel-Lindau disease in the patient. Serial measurement of serum PSA level on follow-up showed increasing levels, which reached to 11.3&#xA0;ng/ml, 15-months after radical prostatectomy. The patient was given post-operative hormone therapy, after which his PSA levels started declining. On last follow-up, 20-months after the radical prostatectomy, he was doing well with serum PSA level of 0.53&#xA0;ng/ml.<fig id="Fig1"><label>Fig. 1</label><caption><p>Microphotographs of the lesion. <bold>a</bold> Clear cell carcinoma very similar to clear cell type of renal cell carcinoma with usual prostatic adenocarcinoma on upper right corner of the photograph (Hematoxylin and eosin stain, 200&#xD7;). <bold>b</bold> The lesional clear cells show immunostaining for pancytokeratin (Diaminobenzidine, 200&#xD7;). <bold>c</bold> The clear cells show CD 10 immunoreactivity (Diaminobenzidine, 400&#xD7;). <bold>d</bold> The lesional clear cells are negative for PSA immunostaining. Note that usual prostatic adenocarcinoma seen in upper left corner of the photograph show positive PSA immunostaining (Diaminobenzidine, 200&#xD7;)</p></caption><graphic xlink:href="13000_2015_432_Fig1_HTML" id="MO1"/></fig></p>
      <p>This case represented a diagnostic challenge because of close resemblance with clear cell renal cell carcinoma (RCC) on histology. Clear cell type is the most common variant of RCC, which shows tubules and solid nests/sheets of clear cells (atypical enlarged nuclei with prominent nucleoli) with surrounding richly vascularized stroma containing interstitial inflammatory cells [<xref ref-type="bibr" rid="CR2">2</xref>]. RCC demonstrates immunopositivity for low molecular weight cytokeratin and vimentin, while it is negative for HMWCK, CK7, CK20, PSA and CEA [<xref ref-type="bibr" rid="CR2">2</xref>]. In addition, most of the clear cell RCCs are positive for epithelial membrane antigen and CD10 [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>RTCCC of the prostate is a novel entity, which was first reported by Singh <italic>et al</italic>. [<xref ref-type="bibr" rid="CR2">2</xref>]<italic>.</italic> Our literature search has revealed only four previously published case-reports of RTCCC of the prostate, which are given in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. Histopathological and immunohistochemical features of RTCCC of the prostate resemble with the clear cell RCC [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>]. In such a situation, it becomes difficult for pathologists to rule out metastasis of clear cell RCC to the prostate. However, to our knowledge, metastasis of RCC to the prostate at initial diagnosis has not been reported. Metastatic involvement of the prostate by primary RCC has been reported in only two cases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Such a metastasis of RCC also presents with detectable lesion in the kidney as well as metastasis involving the lung and the bone. In our case, ultrasound and MRI examinations did not reveal any lesion in the kidney along with the unremarkable appearances of urinary bladder and urethra. MDP bone scan did not reveal skeletal metastasis. Markedly raised level of serum PSA indicated prostatic origin of the malignancy, which was later confirmed by immunohistochemistry. Clear cell lesion in the present case demonstrated an immunohistochemical profile almost identical to that of RCC, with positive expression of CD10, EMA, and vimentin and a negative result for HMWCK, CK7 and PSA, which is similar to the previously described studies on RTCCC of the prostate [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Cases of renal-type clear cell carcinoma of the prostate in literature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>S.No.</th><th>Author (Year)[Ref]</th><th>Age (years)</th><th>Serum PSA at diagnosis</th><th>Type of specimen</th><th>Microscopy</th><th>Special stain</th><th>Immunohistochemistry</th><th>Outcome (Follow-up duration)</th></tr></thead><tbody><tr><td rowspan="2">1.</td><td rowspan="2">Singh et al. (2003) [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td rowspan="2">73</td><td rowspan="2">1.5&#xA0;mg/dl</td><td rowspan="2">TURP followed by radical cystoprostatectomy&#x2009;+&#x2009;pelvic lymph node dissection</td><td rowspan="2">Clear cell carcinoma similar to RCC and typical prostatic adenocarcinoma (Gleason&#x2019;s score 3&#x2009;+&#x2009;3)</td><td rowspan="2">Mucicarmine staining for intracytoplasmic mucin: negative</td><td>Positive: Vimentin, EMA, LMWCK and CD10</td><td rowspan="2">No evidence of disease (7&#xA0;months)</td></tr><tr><td>Negative: PSA, PSAP, S-100, HMB-45, Broad&#xA0;spectrum cytokeratin (AE1/AE3),&#xA0;CK7, CK20, HMWCK, CA-125, CEA,&#xA0;ER and PR</td></tr><tr><td rowspan="2">2.</td><td rowspan="2">Pal &amp; Chowdhury (2007) [<xref ref-type="bibr" rid="CR3">3</xref>]</td><td rowspan="2">64</td><td rowspan="2">2.1&#xA0;ng/L</td><td rowspan="2">TURP</td><td rowspan="2">Clear cell carcinoma similar to RCC</td><td rowspan="2">Mucicarmine staining for intracytoplasmic mucin : negative</td><td>Positive: Pancytokeratin, Vimentin and EMA</td><td rowspan="2">No evidence of pelvic lymph node metastasis (12&#xA0;months)</td></tr><tr><td>Negative: PSA, PSAP and HMWCK</td></tr><tr><td>3.</td><td>Permi et al. (2011) [<xref ref-type="bibr" rid="CR4">4</xref>]</td><td>64</td><td>82&#xA0;ng/ml</td><td>TURP followed by radical cystoprostatectomy&#x2009;+&#x2009;pelvic lymph node dissection</td><td>Clear cell carcinoma similar to RCC</td><td>Not done</td><td>Not done</td><td>No evidence of recurrence (12&#xA0;months)</td></tr><tr><td rowspan="2">4.</td><td rowspan="2">Wang et al. (2015) [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td rowspan="2">64</td><td rowspan="2">10.2&#xA0;ng/ml</td><td rowspan="2">TURP</td><td rowspan="2">Clear cell carcinoma similar to RCC and typical prostatic adenocarcinoma (Gleason&#x2019;s score 4&#x2009;+&#x2009;4)</td><td rowspan="2">Not done</td><td>Positive: LMWCK, Vimentin, EMA, CD10, PSAP and AMACR</td><td rowspan="2">Death due to multiorgan failure (6&#xA0;months)</td></tr><tr><td>Negative: HMWCK, CEA, Broad spectrum cytokeratin and PAX8</td></tr><tr><td rowspan="2">5.</td><td rowspan="2">Present case (2015)</td><td rowspan="2">72</td><td rowspan="2">65.2&#xA0;ng/ml</td><td rowspan="2">Radical prostatectomy and pelvic lymphadenectomy</td><td rowspan="2">Clear cell carcinoma similar to RCC and typical prostatic acinar adenocarcinoma (Gleason&#x2019;s score 4&#x2009;+&#x2009;4)</td><td rowspan="2">Periodic acid Schiff for intracytoplasmic droplets: Positive</td><td>Positive: Pancytokeratin, EMA, CD10, Vimentin and AMACR</td><td rowspan="2">Alive with controlled serum PSA levels (20&#xA0;months)</td></tr><tr><td>Negative: HMWCK (34&#x3B2;E12), CK7, PSA and PAX8</td></tr></tbody></table><table-wrap-foot><p>
<italic>Ref</italic> Reference in the text, <italic>PSA</italic> prostate specific antigen, <italic>TURP</italic> Transurethral resection of prostate, <italic>RCC</italic> renal cell carcinoma, <italic>EMA</italic> epithelial membrane antigen, <italic>LMWCK</italic> low molecular weight cytokeratin, <italic>PSAP</italic> prostate specific acid phosphatase, <italic>HMWCK</italic> high molecular weight cytokeratin, <italic>CEA</italic> carcinoembryonic antigen, <italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor, <italic>AMACR</italic> alpha-methylacyl-CoA racemase</p></table-wrap-foot></table-wrap></p>
      <p>RTCCC of the prostate has been seen in patients of age 60&#xA0;years and above. This recently described entity may show elevation of serum PSA, which is due to co-existing areas of typical prostatic acinar adenocarcinoma. In our case, immunoreactivity of PSA was seen in typical prostatic acinar adenocarcinoma but not in the clear cells. However, the clear cells did express AMACR (P504S), which is a marker for prostatic origin. Management of RTCCC of the prostate is same as that of prostatic adenocarcinoma; however, its biological significance and prognosis is not clear until the date. Death has occurred in a case of RTCCC of the prostate due to multi-organ failure, after 6-months of surgery.</p>
    </sec>
    <sec id="Sec3">
      <title>Conclusions</title>
      <p>Clear cell carcinoma resembling with clear cell renal carcinoma in the prostate indicates diagnosis of renal-type clear cell carcinoma. Imaging studies, serum PSA levels, and immunohistochemistry is essential for the diagnosis. RTCCC of the prostate is a rare and novel pathological entity, which shares histological and immunohistochemical similarity with clear cell RCC. Further research is required to clarify pathogenic mechanisms and biological behavior of this unique tumor.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AMACR</term>
          <def>
            <p>Alpha-methylacyl-CoA racemase</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>Carcinoembryonic antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CK20</term>
          <def>
            <p>Cytokeratin 20</p>
          </def>
        </def-item>
        <def-item>
          <term>CK7</term>
          <def>
            <p>Cytokeratin 7</p>
          </def>
        </def-item>
        <def-item>
          <term>EMA</term>
          <def>
            <p>Epithelial membrane antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>ER</term>
          <def>
            <p>Estrogen receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>HMWCK</term>
          <def>
            <p>High-molecular weight cytokeratin</p>
          </def>
        </def-item>
        <def-item>
          <term>LMWCK</term>
          <def>
            <p>Low molecular weight cytokeratin</p>
          </def>
        </def-item>
        <def-item>
          <term>MDP</term>
          <def>
            <p>99mTc-methylene diphosphonate</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>PR</term>
          <def>
            <p>Progesterone receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>PSA</term>
          <def>
            <p>Prostate-specific antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>PSAP</term>
          <def>
            <p>Prostate specific acid phosphatase</p>
          </def>
        </def-item>
        <def-item>
          <term>RCC</term>
          <def>
            <p>Renal cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>RTCCC</term>
          <def>
            <p>Renal-type clear cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>TURP</term>
          <def>
            <p>Transurethral resection of prostate</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>SP carried out the histopathological and immuhohistochemical studies, conceived the study, drafted, edited, and revised the manuscript. NJ collected the data, did literature search and drafted the manuscript. RK searched the literature, drafted, and critically revised the manuscript. ST participated in the conception and design of the study and performed the clinical studies. UD conceived the study, participated in the clinical studies, and helped to draft the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; information</bold>
        </p>
        <p>SP (MBBS, MD): Assistant Professor, Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. NJ (MBBS): Junior Resident, Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. RK (MBBS, MD): Service Senior Resident, Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. ST (MS, MCh): Associate Professor, Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. UD (MS, MCh): Professor &amp; Head, Department of Urology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Authors are grateful to Mr. Kanhaiya Lal, Mr. Vikash Agrawal and Mr. Yogendra K. Verma for their assistance in immunohistochemistry.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humphrey</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Clear cell neoplasms of the urinary tract and male reproductive system</article-title>
          <source>Semin Diagn Pathol</source>
          <year>1997</year>
          <volume>14</volume>
          <fpage>240</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">9383824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Flores-Sandoval</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Abrams</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Renal-type clear cell carcinoma occurring in the prostate</article-title>
          <source>Am J Surg Pathol</source>
          <year>2003</year>
          <volume>27</volume>
          <fpage>407</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200303000-00016</pub-id>
          <pub-id pub-id-type="pmid">12604899</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pal</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Chowdhury</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>Renal type clear cell carcinoma of prostate</article-title>
          <source>Indian J Surg</source>
          <year>2007</year>
          <volume>69</volume>
          <fpage>81</fpage>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Permi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Laxminarayana</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Yeshvanth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shetty</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Renal type clear cell carcinoma of the prostate: a diagnostic dilemma</article-title>
          <source>J Lab Physicians</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>132</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.4103/0974-2727.86853</pub-id>
          <pub-id pub-id-type="pmid">22219575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Renal-type clear cell carcinoma of the prostate: a case report</article-title>
          <source>Oncol Lett</source>
          <year>2015</year>
          <volume>9</volume>
          <fpage>2149</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">26137029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sangoi</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Bonventre</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>2011</year>
          <volume>35</volume>
          <fpage>678</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e3182152629</pub-id>
          <pub-id pub-id-type="pmid">21490444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cihak</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>R</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Koenen</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Chinchinian</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Metastatic renal carcinoma to the prostate gland: presentation as prostatic hypertrophy</article-title>
          <source>J Urol</source>
          <year>1980</year>
          <volume>123</volume>
          <fpage>791</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">6158583</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Centeno</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Saldivar</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Sarosdy</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Renal cell carcinoma metastatic to the gallbladder or prostate: two case reports</article-title>
          <source>Urology</source>
          <year>1995</year>
          <volume>46</volume>
          <fpage>722</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1016/S0090-4295(99)80310-0</pub-id>
          <pub-id pub-id-type="pmid">7495130</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
